TABLE 1.

Antiproliferative and mesenchymal–epithelial transition factor (c-Met) kinase inhibitory activities of the target compounds.

Compounds	X	R1	Z	IC50 (μM) a
				A549	MCF-7	Hela	c-Met
16a	H	H		12.36 ± 0.97	13.76 ± 1.23	21.54 ± 1.78	0.794
16b	H	H		6.46 ± 0.33	7.87 ± 0.42	12.16 ± 1.08	0.379
16c	H	H		5.58 ± 0.75	6.45 ± 0.81	14.31 ± 1.15	0.345
16d	H	H		12.35 ± 0.98	11.52 ± 1.06	19.53 ± 1.94	0.722
16e	H	H		5.44 ± 0.42	7.13 ± 0.63	11.19 ± 0.96	0.342
16f	H	H		27.33 ± 0.86	>50	>50	>1
16 g	F	H		8.21 ± 0.65	9.17 ± 1.03	17.73 ± 1.29	0.658
16 h	F	H		6.56 ± 0.42	8.18 ± 1.12	13.94 ± 1.59	0.437
16i	F	H		17.35 ± 0.97	19.03 ± 1.32	24.96 ± 2.17	ND b
16j	F	H		3.26 ± 0.67	3.68 ± 0.34	6.17 ± 0.58	0.110
16 k	F	H		6.18 ± 0.34	6.51 ± 0.63	12.89 ± 1.06	0.380
16l	F	H		11.44 ± 0.76	11.97 ± 1.24	23.32 ± 2.12	0.725
17a	H	CH3		1.23 ± 0.13	1.43 ± 0.21	2.31 ± 0.29	0.055
17b	H	CH3		4.31 ± 0.49	5.15 ± 0.72	9.46 ± 0.58	0.245
17c	H	CH3		7.68 ± 0.71	8.79 ± 0.89	15.88 ± 1.10	0.532
17d	H	CH3		5.21 ± 0.37	6.95 ± 0.67	10.73 ± 1.42	0.289
17e	H	CH3		2.05 ± 0.19	1.74 ± 0.22	4.78 ± 0.43	0.077
17f	H	CH3		5.73 ± 0.54	6.38 ± 0.85	12.37 ± 1.53	0.300
17 g	F	CH3		4.65 ± 0.66	4.83 ± 0.33	9.25 ± 0.45	0.232
17 h	F	CH3		3.56 ± 0.32	4.25 ± 0.76	7.43 ± 0.38	0.156
17i	F	CH3		188	25.44 ± 1.54	>50	ND
17j	F	CH3		7.16 ± 0.45	7.31 ± 0.77	14.18 ± 1.64	0.450
17 k	F	CH3		15.34 ± 0.51	18.17 ± 1.28	25.33 ± 2.40	ND
17l	F	CH3		0.98 ± 0.08	1.05 ± 0.17	1.28 ± 0.25	0.026
17 m	F	CH3		8.84 ± 0.97	9.34 ± 1.03	17.37 ± 1.56	0.653
Foretinib c	-	-	-	0.71 ± 0.05	0.93 ± 0.09	1.18 ± 0.25	0.019

Note. A549, human lung adenocarcinoma; MCF-7, human breast cancer; Hela, human cervical carcinoma.

^aThe values are the average of two separate determinations.

^bND, not detected.

^cUsed as a positive control.